Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

This study is currently recruiting participants.

Verified November 2010 by Ludwig-Maximilians - University of Munich

Sponsor:

Collaborator:

Roche Pharma AG

Information provided by:

Ludwig-Maximilians - University of Munich

ClinicalTrials.gov Identifier:

NCT01249638

First received: November 29, 2010

Last updated: March 11, 2011

Last verified: November 2010

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2016
Estimated Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)

No publications provided by Ludwig-Maximilians - University of Munich

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. BMC Cancer. 2011 Aug 23;11:367.

To Top